ReviewBioMed research international2013
The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease.
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis.Journal of Alzheimer's disease : JAD · 2017Pooled it
- Spatial-temporal lipidomics reveals dysregulated lipid metabolism in mouse brain during Alzheimer's disease progression.Journal of advanced research · 2026Article
- Amyloid β-Cholesterol Interplay: Removal of Cholesterol From the Membranes to Catalyze Aggregation and Amyloid Pathology.Journal of neurochemistry · 2026Article
- Intelligent Alzheimer's Diseases Gene Association Prediction Model Using Deep Regulatory Genomic Neural Networks.Journal of Alzheimer's disease reports · 2024Article
- Decreased DHA-containing phospholipids in the neocortex of dementia with Lewy bodies are associated with soluble AβBrain pathology (Zurich, Switzerland) · 2023Article
- Simultaneous DHA and organic selenium production by Schizochytrium sp.: a theoretical basis.Scientific reports · 2023Article
- Gemfibrozil-Induced Intracellular Triglyceride Increase in SH-SY5Y, HEK and Calu-3 Cells.International journal of molecular sciences · 2023Article
- Vitamin B12 Attenuates Changes in Phospholipid Levels Related to Oxidative Stress in SH-SY5Y Cells.Cells · 2022Article
- Methylxanthines Induce a Change in the AD/Neurodegeneration-Linked Lipid Profile in Neuroblastoma Cells.International journal of molecular sciences · 2022Article
- Mechanistic Link between Vitamin B12 and Alzheimer's Disease.Biomolecules · 2022Review
- High-Fat Diet Alleviates Neuroinflammation and Metabolic Disorders of APP/PS1 Mice and the Intervention With Chinese Medicine.Frontiers in aging neuroscience · 2021Article
- Sialometabolism in Brain Health and Alzheimer's Disease.Frontiers in neuroscience · 2021Review
- The impact of capsaicinoids on APP processing in Alzheimer's disease in SH-SY5Y cells.Scientific reports · 2020Article
- High Speed AFM and NanoInfrared Spectroscopy Investigation of AβFrontiers in molecular biosciences · 2020Article
- Poster Viewing Sessions PB01-B01 to PB03-V09.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2019Article
- ApoE4: an emerging therapeutic target for Alzheimer's disease.BMC medicine · 2019Review
- Characterization of the unique In Vitro effects of unsaturated fatty acids on the formation of amyloid β fibrils.PloS one · 2019Article
- Quantitative Systems Pharmacology Model for Alzheimer Disease Indicates Targeting Sphingolipid Dysregulation as Potential Treatment Option.CPT: pharmacometrics & systems pharmacology · 2018Article
- The emerging roles of protein homeostasis-governing pathways in Alzheimer's disease.Aging cell · 2018Review
- Guanosine monophosphate reductase 1 is a potential therapeutic target for Alzheimer's disease.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a devastating neurodegenerative disorder currently affecting over 35 million people worldwide. Pathological hallmarks of AD are massive amyloidosis, extracellular senile plaques, and intracellular neurofibrillary tangles accompanied by an excessive loss of synapses. Major constituents of senile plaques are 40-42 amino acid long peptides termed β -amyloid (A β ). A β is produced by sequential proteolytic processing of the amyloid precursor protein (APP). APP processing and A β production have been one of the central scopes in AD research in the past. In the last years, lipids and lipid-related issues are more frequently discussed to contribute to the AD pathogenesis. This review summarizes lipid alterations found in AD postmortem brains, AD transgenic mouse models, and the current understanding of how lipids influence the molecular mechanisms leading to AD and A β generation, focusing especially on cholesterol, docosahexaenoic acid (DHA), and sphingolipids/glycosphingolipids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.